Neumora Therapeutics Inc (NASDAQ: NMRA) kicked off on Tuesday, down -1.33% from the previous trading day, before settling in for the closing price of $9.80. Over the past 52 weeks, NMRA has traded in a range of $8.33-$21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 55.65%. With a float of $54.33 million, this company’s outstanding shares have now reached $160.48 million.
Let’s look at the performance matrix of the company that is accounted for 124 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Neumora Therapeutics Inc is 66.37%, while institutional ownership is 29.78%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 55.65% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Take a look at Neumora Therapeutics Inc’s (NMRA) current performance indicators. Last quarter, stock had a quick ratio of 10.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics Inc (NASDAQ: NMRA) saw its 5-day average volume 0.64 million, a negative change from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 37.56%. Additionally, its Average True Range was 0.72.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 4.21%, which indicates a significant decrease from 12.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.46% in the past 14 days, which was lower than the 68.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.60, while its 200-day Moving Average is $12.10. Nevertheless, the first resistance level for the watch stands at $9.81 in the near term. At $9.95, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.06. If the price goes on to break the first support level at $9.56, it is likely to go to the next support level at $9.45. Assuming the price breaks the second support level, the third support level stands at $9.31.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
The company with the Market Capitalisation of 1.56 billion has total of 161,561K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -235,930 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -72,550 K.
